| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Special Articles |
Departments of Human Genetics (E.V.) and Pediatrics (E.V., E.R.B.M.), University of California School of Medicine, Los Angeles, California 90095; Service de Pédiatrie, Hôpital Charles Nicolle (C.L.), Rouen, France; Service de Biologie, Hôpital Val-de-Grâce (F.D.), Paris, France; the Department of Pediatrics and Genetics, Stanford University Medical School (M.A.K.), Stanford, California; and Service de Génétique Médicale, Hôpital Necker-Enfants Malades (M.L.M., P.M.), Paris, France
Address all correspondence and requests for reprints to: Eric Vilain, M.D., Ph.D., Department of Human Genetics, University of California School of Medicine, Gonda Center, Room 6357, 695 Charles E. Young Drive, Los Angeles, California 90095-7088. E-mail: evilain{at}ucla.edu
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The X-linked or cytomegalic form of AHC is an inherited disorder of adrenal cortical development (1, 2), and is characterized by the absence or near absence of the permanent or adult zone of the adrenal cortex and by structural disorganization of the fetal cortex with abnormally large cells (3, 4). It differs from the autosomal recessive miniature adult form of AHC, in which the adrenal cortexes have the normal adult structure but are very small (5). X-Linked AHC results in severe primary adrenal insufficiency involving glucocorticoids and mineralocorticoids and failure to respond to the elevated levels of ACTH (2). Symptoms usually have a sudden onset and are precipitated by stress, such as an intercurrent infection or surgical procedure. Symptoms include hypotension, dehydration, shock, abdominal pain, and fever, accompanied by hyponatremia and hyperkalemia. If untreated, the disorder is lethal. The age of onset is usually in the neonatal period or during infancy. However, in some patients, age of onset is later, up to several years of age, presumably due to residual functional cortex (2). Hypogonadotropic hypogonadism, manifesting clinically with cryptorchidism and delayed puberty, is also frequently associated with AHC (6, 7, 8).
AHC may occur as an isolated disorder or as part of a contiguous gene syndrome with glycerol kinase deficiency and Duchenne muscular dystrophy (9). Intragenic mutations in DAX1 (Dosage-sensitive sex reversal, Adrenal hypoplasia congenita on the X-chromosome, gene 1), a gene encoding a new member of the nuclear hormone receptor superfamily, were shown to be responsible for both AHC and hypogonadotropic hypogonadism (10, 11, 12). DAX1 is located in the Xp21 dosage-sensitive sex reversal region, the duplication of which is associated with female or ambiguous genitalia in XY individuals (13, 14). Analysis of DAX1 has shown that many AHC patients have DAX1 mutations, but some individuals with AHC have no detectable DAX1 mutations (2, 10). The mouse DAX1 homolog, Ahch, is expressed in the adrenals on embryonic day 12.5, 1 day after the development of the adrenal primordium from the urogenital ridge, and expression persists (15). Point mutations in DAX1 in patients with AHC, and murine expression profile of Ahch suggest that DAX1 is required for the normal development of the adrenal cortex. DAX1 may interact in a concerted fashion with steroidogenic factor-1 (SF1), another member of the nuclear hormone receptor superfamily (16).
We report three unrelated boys with a previously unrecognized syndrome that we will refer to as the IMAGe association for Intrauterine growth retardation, Metaphyseal dysplasia, Adrenal hypoplasia congenita, and Genital abnormalities. We will describe additional clinical, radiological, and molecular genetic findings in these boys, including an absence of mutations in the DAX1 gene.
| Materials and Methods |
|---|
|
|
|---|
Blood samples for investigational studies were obtained from patients with informed consent. Genomic DNA samples were extracted using standard procedures. For DAX1 amplification, primers and cycle conditions were those that have been previously described (17, 18). For SF1 amplification, the following intronic primers were used for the protein coding exons: 5'-CACAGAGAGGGGATTACGCGA-3' and 5'-GTACTATCCCCTCAGCCCCT-3' for exons 2 and 3, 5'-CCATGAAAGGGTGTTGAGCA-3' and 5'-GATGGCCCTATCCAAAGGACA-3' for exon 4, 5'-ACGCCTAGTTGGGTCTCAGT-3' and 5'-ACAGCAGGGCTACCTCTCCA-3' for exon 5, and 5'-GTGCACCTCCAATCCATGCCC-3' and 5'-ACTCTGGCCACAGCAGGGCTA-3' for exon 6. Amplification conditions for SF1 were 5-min initial denaturation at 94 C, followed by 1-min denaturation at 94 C, 1-min annealing at 57 C, and 1-min extension at 72 C for 30 cycles, followed by a 7-min final extension at 72 C.
Direct sequencing was performed on the amplification products by automated cycle sequencing, using an ABI 377 (PE Applied Biosystems, Foster City, CA). Southern blots were performed (19); DAX1 exon 2 (17) was used as a probe, with patients genomic DNAs digested with TaqI.
| Results |
|---|
|
|
|---|
|
This French Caucasian boy presented at birth with intrauterine
growth retardation and left hydronephrosis. He had bifrontal bossing, a
flattened nasal bridge (that progressively improved), low set ears,
bilateral cryptorchidism, and a micropenis (length, 2 cm; <5th
percentile); (Fig. 1a
). He was
hypotonic. On day 13, a nephrostomy drainage tube was inserted under
general anesthesia, and acute adrenal insufficiency was revealed by
generalized weakness, vomiting, and a dehydrated appearance immediately
after the surgery. Hyponatremia, hyperkalemia, and hypernatriuria were
noted. His plasma ACTH level was 720 pg/mL (normal, 1060 pg/mL).
Replacement doses of fludrocortisone and hydrocortisone, and sodium
supplementation were initiated. An ACTH stimulation test was performed,
and intermediates in the mineralocorticoid and glucocorticoid
biosynthetic pathways were either low or within normal limits:
17-hydroxyprogesterone, 30 ng/dL (normal, 777 ng/dL);
androstenedione, 100 ng/dL (normal, 20290 ng/dL);
dehydroepiandrosterone, 35 ng/dL (normal, 50760 ng/dL);
11-desoxycortisol, 30 ng/dL (normal, 13147 ng/dL);
deoxycorticosterone, 5 ng/dL (normal, 749 ng/dL); and
17-hydroxypregnenolone, 20 ng/dL (normal, 36769 ng/dL). He had a
normal testosterone response after hCG stimulation. The proposed
diagnosis was AHC.
|
He had normal creatine phosphokinase levels at 18 U/mL. There was no glyceroluria on urinary organic acid chromatography, and triglycerides were normal, suggesting normal glycerol kinase activity.
The GH level measured at 2 yr, 5 months of age after stimulation by clonidine was 36.7 ng/mL (normal, >10 ng/mL). At 4 yr of age, after stimulation by ornithine, it was 20.3 ng/mL. The level of insulin-like growth factor I at 4 yr of age was 3.8 U/L (normal, 35.5 U/L).
Family history was unremarkable. High resolution chromosome
analysis revealed a normal 46,XY karyotype. No mutation was identified
in either the DAX1- or SF1-coding sequences. A
Southern blot performed with DAX1 exon 2 as probe to look
for a deletion or rearrangement was normal. Intellectual development
was normal. Growth retardation and muscular hypotonia persisted, and
metaphyseal and epiphyseal dysplasia was first noted at 2 yr of age,
associated with progressively severe scoliosis (Fig. 1b
). X-Rays
performed at 6 yr of age showed small, irregular and flattened femoral
and tibial epiphyses and enlarged, striated, and irregular femoral
metaphyses (Fig. 1c
).
Patient 2
This French Caucasian boy was diagnosed with intrauterine growth
retardation during the second trimester of pregnancy. He was delivered
at 33 weeks gestation, and Apgar scores were 3 and 6. He developed
respiratory distress requiring intubation. He was noted to have
micrognathia, low set ears, and a flattened nasal bridge (Fig. 2a
). His phallus was small (1.8 cm; <5th
percentile), and he had bilateral cryptorchidism. On day 4,
hyponatremia, hypernatriuria, and hyperpigmentation were noted. ACTH
was elevated to 1600 pg/mL (normal, 1080 pg/mL). Intermediates in the
mineralocorticoid and glucocorticoid biosynthetic pathways were low,
with 17-hydroxyprogesterone at 2 ng/dL (normal, 26568 ng/dL) and
11-desoxycortisol undetectable (normal, 4857 ng/dL). His skin
darkened progressively over the next 2 weeks. Abdominal ultrasound and
abdominal computed tomography scan did not reveal the presence of
adrenals. A diagnosis of AHC was proposed.
|
The family history was unremarkable. High resolution chromosome analysis showed a normal 46,XY karyotype. No mutation was identified in either the DAX1- or SF1-coding sequences. A Southern blot performed with the DAX1 exon 2 probe was normal.
Intellectual development was normal. Adrenal insufficiency was treated
on day 17 with replacement doses of hydrocortisone and fludrocortisone
and increased sodium chloride intake. A metaphyseal dysplasia was noted
at age 3 yr, 8 months when x-rays showed striated, irregular, and
flared femoral and tibial metaphyses (Fig. 2b
). Spinal x-rays revealed
osteopenia but no scoliosis (Fig. 2c
). Bone age was delayed.
Patient 3
This American Latino boy presented at birth with severe
intrauterine growth retardation, dysmorphic features, and marked
hyperpigmentation leading to the diagnosis of charcoal-baby syndrome
and a subsequent report (21). He had a prominent forehead, secondary to
overriding, but movable sagittal and coronal sutures, and bilateral
epicanthal folds (Fig. 3a
). His ears were
low set. He had micrognathia and a slightly high arched palate with a
uvula that had a very short cleft. He had bilateral cryptorchidism with
a small penis (3 cm at 6 months of age; 10th percentile). Liver and
spleen calcifications that had been seen on ultrasound prenatally were
confirmed postnatally by ultrasound.
|
At 2 yr of age, femoral metaphyses were noted to be irregular and
flared, and epiphyses were small (Fig. 3b
). His intellectual
development was normal. Family history was unremarkable. High
resolution karyotype was 46,XY with no abnormalities. No mutation was
identified in either the DAX1- or SF1-coding
sequences. A Southern blot performed with the DAX1 exon 2
probe was normal.
| Discussion |
|---|
|
|
|---|
The skeletal anomalies observed in our patients do not have specific characteristics of well defined chondrodysplasia. The normal hand size rules out pathologies caused by mutations in COMP, such as multiple epiphyseal dysplasia (OMIM 132400). An association between skeletal dysplasia and congenital adrenal hypoplasia has not been described previously. However, patients with the Xp21 contiguous gene syndrome involving AHC, glycerol kinase deficiency, and Duchenne muscular dystrophy may have osteoporosis and pathological fractures (26). The abnormalities in calcium metabolism observed or presumed in our patients are also remarkable, because it is extremely rare for chondrodysplasia to be associated with calcium metabolism abnormalities. The Jansen-type metaphyseal chondrodysplasia, caused by a mutation in the gene encoding the PTH receptor (27), is the only well characterized example of the association of chondrodysplasia with an abnormality in calcium metabolism (28). Because of the low incidence of AHC or metaphyseal/epiphyseal dysplasia, this association in three unrelated patients is unlikely to be coincidental and may be explained by a unifying molecular mechanism.
The genital anomalies may be the consequence of hypogonadotropic hypogonadism, as cryptorchidism and micropenis are frequently observed in this condition, as with AHC consequent to DAX1 mutations. Stimulation tests, difficult to interpret in the prepubertal period, were not performed in our patients to confirm this possibility.
Two hypotheses may explain the pathophysiology of this newly recognized clinical association. 1) A mutation in an autosomal gene may be responsible for the AHC present in these patients. This autosomal gene could be directly involved in both adrenal and bone development or could be localized near a second, discrete locus responsible for the bone dysplasia and involved in a contiguous gene syndrome with the autosomal AHC locus. According to this hypothesis, the fact that these three patients as well as the two others reported previously (22, 23) are male would be coincidental. It is possible that AHC in females is underreported, because localization of the DAX1-AHC locus on the X-chromosome has focused attention of clinicians on adrenal insufficiency in boys (2).
2) A mutation in the DAX1 gene region, leaving the DAX1 open reading frame intact, may occur. According to this hypothesis, AHC would be explained by a position effect leading to a low expression of DAX1. Decreased DAX1 protein production would also be responsible for the genital anomalies, because mutations in DAX1 are known to be present in patients with AHC and hypogonadotropic hypogonadism. The bone abnormalities would be explained by the presence of a locus involved in bone development near DAX1. DAX1 expression may be disrupted by a distant rearrangement, as one patient with AHC has a breakpoint localized up to 100 kb centromeric of DAX1 (11). The presence of a bone development locus in Xp21.3 is plausible, because approximately half of the patients with large deletions of the region have osteoporosis and pathological fractures (26). Precise characterization of the Xp21.3 deletions in patients with and without bone involvement may help to define a critical region on the X-chromosome crucial for normal bone development and/or susceptibility to osteoporosis.
In summary, we report three boys with a new syndrome, the IMAGe association, who have intrauterine growth retardation, metaphyseal dysplasia, AHC, and genital abnormalities. Identification of additional patients with these clinical features will help delineate the clinical spectrum of this syndrome and may give us insight into its molecular pathogenesis.
| Footnotes |
|---|
Received April 15, 1999.
Revised August 23, 1999.
Accepted August 25, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
T. Else Telomeres and telomerase in adrenocortical tissue maintenance, carcinogenesis, and aging J. Mol. Endocrinol., October 1, 2009; 43(4): 131 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ferraz-de-Souza, F. Martin, D. Mallet, R. E. Hudson-Davies, P. Cogram, L. Lin, D. Gerrelli, F. Beuschlein, Y. Morel, A. Huebner, et al. CBP/p300-Interacting Transactivator, with Glu/Asp-Rich C-Terminal Domain, 2, and Pre-B-Cell Leukemia Transcription Factor 1 in Human Adrenal Development and Disease J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 678 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lin, W.-X. Gu, G. Ozisik, W. S. To, C. J. Owen, J. L. Jameson, and J. C. Achermann Analysis of DAX1 (NR0B1) and Steroidogenic Factor-1 (NR5A1) in Children and Adults with Primary Adrenal Failure: Ten Years' Experience J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3048 - 3054. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Bergada, G. del Rey, P. Lapunzina, C. Bergada, M. Fellous, and S. Copelli Familial Occurrence of the IMAGe Association: Additional Clinical Variants and a Proposed Mode of Inheritance J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3186 - 3190. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Perry, O. Kecha, J. Paquette, C. Huot, G. Van Vliet, and C. Deal Primary Adrenal Insufficiency in Children: Twenty Years Experience at the Sainte-Justine Hospital, Montreal J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3243 - 3250. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Hammer, K. L. Parker, and B. P. Schimmer Minireview: Transcriptional Regulation of Adrenocortical Development Endocrinology, March 1, 2005; 146(3): 1018 - 1024. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |